What are common mistakes to avoid during FDA inspections?

FDA inspections are high-stakes. A single Form 483 can trigger a warning letter that freezes new drug approvals, and per FDA data, 62% of drugs that entered shortage between 2013 and 2017 were tied to manufacturing or product quality problems. Even experienced quality teams make avoidable mistakes during inspections. Below are the most common ones, and the practical fixes for each.

Common Mistakes Companies Make During FDA Inspections

1. Lack of Preparation

One of the biggest mistakes is failing to adequately prepare. That means outdated documentation, unclear standard operating procedures (SOPs), or staff who haven't been trained on the current CFR requirements. Without proper preparation, companies risk appearing disorganized and non-compliant.

Solution: Establish a comprehensive FDA inspection readiness plan. Regularly update and review SOPs, train staff on compliance procedures, and conduct mock inspections to identify potential gaps.

2. Inadequate Record-Keeping

Incomplete or inaccurate records are a red flag for FDA investigators. Many companies fail to maintain documentation that meets FDA standards: batch records, equipment maintenance logs, cleaning logs, and product testing data.

Solution: Implement a reliable documentation system that ensures accuracy, completeness, and easy accessibility. Use digital tools and software to automate record-keeping and ensure version control.

3. Non-Compliance with Current Good Manufacturing Practices (cGMP)

Failure to adhere to cGMP standards is a recurring issue during inspections. Common violations include improper sanitation, lack of equipment calibration, and unqualified personnel handling critical tasks.

Solution: Conduct regular internal audits to ensure compliance with cGMP standards. Invest in staff training programs and maintain detailed logs of equipment maintenance and cleaning schedules.

4. Untrained Employees

When employees are not adequately trained, they may provide incorrect or inconsistent information during an inspection. This can create an impression of negligence and non-compliance.

Solution: Develop a comprehensive training program that covers all aspects of FDA compliance. Ensure employees are well-versed in their responsibilities and confident in responding to investigator inquiries.

5. Failure to Address Previous Issues

Ignoring or inadequately addressing issues raised in past inspections is a significant mistake. FDA investigators often review corrective actions taken since the last inspection, and recurring problems indicate poor management practices.

Solution: Create a corrective and preventive action (CAPA) plan for any issues identified during inspections. Document all steps taken to resolve problems and ensure they are implemented effectively.

6. Overloading Investigators with Information

Providing excessive or irrelevant information during an inspection can confuse or frustrate investigators. This may lead them to scrutinize areas they initially did not intend to review.

Solution: Provide concise, accurate, and relevant information. Designate a point of contact for the inspection who can efficiently manage requests and responses.

7. Lack of Transparency

Attempting to hide issues or providing incomplete information can escalate problems during an inspection. FDA investigators value honesty and transparency.

Solution: Foster a culture of openness and accountability. If an issue arises during an inspection, address it directly and outline the steps being taken to resolve it.

8. Ignoring FDA Guidelines

Some companies fail to stay updated on FDA guidelines and regulations, leading to unintentional violations. This is particularly problematic in industries with frequent regulatory updates.

Solution: Subscribe to FDA updates and regularly review industry-specific guidelines. Assign a compliance officer to track and communicate regulatory changes to relevant departments.

Consequences of Mistakes During FDA Inspections

Failing an FDA inspection can have severe consequences, including:

• Warning Letters: Official notices from the FDA indicating violations.
• Product Recalls: Mandatory removal of products from the market.
• Fines and Legal Action: Significant financial penalties or legal consequences.
• Reputation Damage: Loss of trust among consumers and stakeholders.